Morgan Stanley Pear Therapeutics, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.21 - $1.24 $3,415 - $20,167	-16,264 Reduced 30.37%	37,296 $9,000
Q4 2022 Feb 14, 2023	BUY	$0.99 - $2.91 $29,032 - $85,338	29,326 Added 121.01%	53,560 $63,000
Q3 2022 Nov 14, 2022	BUY	$0.13 - $2.27 $2,861 - $49,969	22,013 Added 991.13%	24,234 $49,000
Q2 2022 Oct 27, 2022	SELL	$1.54 - $6.48 $5,266 - $22,161	-3,420 Reduced 60.63%	2,221 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.54 - $6.48 $5,266 - $22,161	-3,420 Reduced 60.63%	2,221 $3,000
Q1 2022 Oct 27, 2022	BUY	$3.67 - $7.63 $12,551 - $26,094	3,420 Added 153.98%	5,641 $29,000
Q1 2022 May 13, 2022	BUY	$3.67 - $7.63 $11,813 - $24,560	3,219 Added 132.91%	5,641 $29,000
Q4 2021 Feb 14, 2022	BUY	$4.98 - $10.0 $12,061 - $24,220	2,422 New	2,422 $15,000

23M

Ticker PEAR
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 138,768,992
Market Cap $1.39M
Description
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a softwa...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.